Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Gilead Sciences

Both companies feature coronavirus-related work and solid pipelines. One of them may be poised for renewed revenue growth.

Better Coronavirus Stock: Regeneron or Gilead Sciences?

Sorrento Therapeutics Inc

It's a battle of big vs. little with these two COVID-19-focused biotechs.

Better Coronavirus Stock: Sorrento Therapeutics vs. Regeneron

BioMarin Pharmaceutical

REGN vs. BMRN: Which Stock Is the Better Value Option?

Barnes Group

Ennis

Empire State Realty Trust

Sturm, Ruger & Company

It seems that the bull market has decided to fight back on a Friday, after a horrid selloff on Thursday. If you’re looking to find a couple of names to purchase, here are our Top Buys today from our AI technology.

Recover From Thursday's Bleak Selloff With These Top Stock Market Picks

Regeneron (REGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Regeneron (REGN) Soars to 52-Week High, Time to Cash Out?

Regeneron (REGN) initiates study on its antibody cocktail, REGN-COV2, for the prevention and treatment of COVID-19.

Regeneron Initiates Study on Antibody Cocktail for Coronavirus

In a statement on Thursday, Regeneron Pharmaceuticals (NASDAQ: REGN) said that it has started human trials of its candidate antibodies-based vaccine for COVID-19. Chief Scientific Officer George Yancopoulos also highlighted that the company is using an adaptive approach for human testing.

Regeneron Pharmaceuticals starts human trials of its candidate antibody cocktail for COVID-19

The company is using the same tech to fight the novel coronavirus as it used for its successful Ebola virus treatment.

Regeneron Begins Human Trials of a Potential COVID-19 Treatment

"We hope sooner rather than later we can get answers that can really make a difference," Regeneron's chief scientific officer, Dr. George Yancopoulos, told CNBC on Thursday.

Regeneron sees 'a lot of reason for hope' as human testing of its coronavirus drug begins

Shares of Regeneron Pharmaceuticals Inc. REGN, -0.32% were down 0.1% in premarket trading on Thursday after the company said it started a Phase 1 clinical trial testing its experimental antibody cocktail aimed at both preventing and treating COVID-19.

Regeneron starts clinical study for COVID-19 antibody treatment

TARRYTOWN, N.Y., June 11, 2020 /PRNewswire/ -- Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced updates related...

Regeneron Collaborations on Dupixent® (dupilumab) Highlighted During Sanofi R&D Investor Event

ABIOMED

DexCom

NVIDIA

PayPal

The Nasdaq Composite Index closed on Wednesday above 10,000 for the first time in history as investors continue their optimistic bet on the economy recovering from the coronavirus-related shutdown.

Top-Performing Nasdaq Stocks So Far in 2020

In the latest trading session, Regeneron (REGN) closed at $606.59, marking a -0.33% move from the previous day.

Regeneron (REGN) Stock Moves -0.33%: What You Should Know

Regeneron: Growth Plans In Immuno-Oncology (ASCO Update)

TARRYTOWN, N.Y., June 5, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Goldman Sachs 41st Annual Global Healthcare Conference 2020 at 3:00 p.m. ET on Tuesday, June 9, 2020 Credit Suisse Biotech Management & Board Call...

Regeneron Announces Upcoming Investor Conference Presentations

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Why Is Regeneron (REGN) Up 9.2% Since Last Earnings Report?

Regeneron: Favorable Performance Of Current Product Portfolio, Impressive Pipeline Bode Well For Growth Over The Next Decade

Carrier Global

MarketAxess Holdings

Newmont Mining

NortonLifeLock

ServiceNow

West Pharmaceutical Services

In a year dominated by COVID-19 news, many of the top-performing companies were boosted by the pandemic, but the top performer benefited from longer-term trends.

Top Performers in the S&P 500 This Year

Alibaba

Cheniere Energy Partners

NIKE

Visa

It's hard to fight momentum on Wall Street. Whether the market is surging higher or dropping like a stone, taking the other side of the trade can often end up costing you.

Jeff Reeves's Strength in Numbers: Buy this, not that — 5 stocks to trade into now and 5 to avoid

By the end of 2025, the biotech's revenue could skyrocket to levels that are unimaginable today.

Where Will Regeneron Be in 5 Years?

In the race to develop an effective new coronavirus treatment, one of the West Coast's premier biotechnology companies just got lapped by the oldest pharmaceutical giant in the Midwest.

Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate

Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.

Regeneron Expands Deal With Intellia for Hemophilia Treatments

Regeneron Pharmaceuticals, Inc. (REGN) Regeneron Oncology Investor Event, ASCO 2020 Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Regeneron Oncology Investor Event ASCO 2020 Conference (Transcript)

Intellia Therapeutics Inc. (NASDAQ: NTLA) has announced an expansion to its collaboration with Regeneron Pharmaceuticals Inc.

News for Regeneron Pharmaceuticals Stock (REGN)